IPP Bureau
Apollo Hospitals Chennai reaches 6,000+ successful robotic procedure
By IPP Bureau - August 16, 2024
The robotic surgery program has continually pushed the boundaries of medical technology
Pfizer and BioNTech update on mRNA-based combination vaccine program against Influenza and Covid-19
By IPP Bureau - August 16, 2024
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
HCAH Kolkata Center achieves NABH Certification
By IPP Bureau - August 15, 2024
Becomes the first rehab & recovery center in east India to earn NABH accreditation
Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr
By IPP Bureau - August 15, 2024
India Business grew by 11.9% YoY to Rs. 1196.2 crore
ICMR and Panacea Biotec initiates Phase III clinical trial of DengiAll
By IPP Bureau - August 15, 2024
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Generative AI is a top driver for cloud investments: Wipro FullStride Cloud Report
By IPP Bureau - August 15, 2024
Majority of organizations are looking to increase investments in public and hybrid cloud
Evonik expands its formulation capabilities for lipid nanoparticles
By IPP Bureau - August 15, 2024
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Marksans Pharma Q1 FY25 revenue up 18%
By IPP Bureau - August 14, 2024
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
NHA and MUHS sign MoU to drive digital health education
By IPP Bureau - August 14, 2024
The partnership marks a significant milestone in integrating digital health education into medical curricula
Wanbury appoints Prakash Venkatraman as President of API Business
By IPP Bureau - August 14, 2024
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA
By IPP Bureau - August 14, 2024
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth
By IPP Bureau - August 13, 2024
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
HealthCRED secures US$ 1.2 million in seed funding
By IPP Bureau - August 13, 2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Pfizer announces results of ABRYSVO for RSV in immunocompromised adults
By IPP Bureau - August 13, 2024
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Alembic receives USFDA final approval for Dabigatran Etexilate Capsules, 110 mg
By IPP Bureau - August 13, 2024
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
